Metformin treatment of antipsychotic-induced dyslipidemia: An analysis of two randomized, placebo-controlled trials

Molecular Psychiatry

Volumn 21, Issue 11, 2016, Pages 1537-1544

  Wu, R R ^a   Zhang, F Y ^a,b   Gao, K M ^c   Ou, J J ^a   Shao, P ^a   Jin, H ^d   Guo, W B ^a   Chan, P K ^c   Zhao, J P ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b LIEBER INSTITUTE FOR BRAIN DEVELOPMENT   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CLOZAPINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; OLANZAPINE; PLACEBO; RISPERIDONE; SULPIRIDE; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; LOW DENSITY LIPOPROTEIN; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG THERAPY; DYSLIPIDEMIA; FEMALE; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; BLOOD; BODY WEIGHT; COMPLICATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; DYSLIPIDEMIAS; GLUCOSE BLOOD LEVEL; OBESITY; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; BODY WEIGHT; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LIPOPROTEINS, LDL; MALE; METFORMIN; OBESITY; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 84955579943     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2015.221     Document Type: Article

References (45)

1. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2011; 8: 114-126.
2. Heal DJ, Gosden J, Jackson HC, Cheetham SC, Smith SL. Metabolic consequences of antipsychotic therapy: preclinical and clinical perspectives on diabetes, diabetic ketoacidosis, and obesity. Handb Exp Pharmacol 2012; 212: 135-164.
3. Ruzanna ZZ, Ong LY, Cheah YC, Fairuz A, Marhani M. The association between dyslipidaemia and types of antipsychotic medications among patients with chronic schizophrenia. Med J Malaysia 2012; 67: 39-44.
4. Musil R, Obermeier M, Russ P, Hamerle M. Weight gain and antipsychotics: a drug safety review. Expert Opin Drug Saf 2015; 14: 73-96.
5. Wu RR, Zhao JJ, Liu ZN, Zhai JG, Guo XF, Guo WB et al. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology (Berl) 2006; 186: 572-578.
6. Graham I, Cooney MT, Bradley D, Dudina A, Reiner Z. Dyslipidemias in the prevention of cardiovascular disease: risks and causality. Curr Cardiol Rep 2012; 14: 709-720.
7. Casey DE. Metabolic issues and cardiovascular diseases in patients with psychiatric disorders. Am J Med 2005; 118: 15s-22s.
8. Lambert TJ, Velakoulis D, Pantelis C. Medical comorbidity in schizophrenia. Med J Aust 2003; 178: S67-S70.
9. Jarcho JA, Keaney JF Jr. Proof that lower is better-LDL cholesterol and IMPRO-VE-IT. N Engl J Med 2015; 372: 2448-2450.
10. Chinese Cardiovascular Disease Association. The Guidelines of Dyslipidemia Prevention in China. People Health Press: Beijing, China, 2007.
11. Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW et al. American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis: executive summary. Endocr Pract 2012; 18: 269-293.
12. Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW et al. American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract 2012; 18: 1-78.
13. Izkhakov E, Meltzer E, Rubinstein A. Pathogenesis and management of diabetic dyslipidemia. Treat Endocrinol 2003; 2: 231-245.
14. Wu RR, Jin H, Gao K, Twamley EW, Ou JJ, Shao P et al. Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study. Am J Psychiatry 2012; 169: 813-821.
15. Wu RR, Zhao JP, Guo XF, He YQ, Fang MS, Guo WB et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatry 2008; 165: 352-358.
16. Wu RR, Zhao JP, Jin H, Shao P, Fang MS, Guo XF et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 2008; 299: 185-193.
17. Grundy SM. Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance. Clin Cornerstone 2006; 8: S21-S27.
18. Soleimani M. Insulin resistance and hypertension: new insights. Kidney Int 2015; 87: 497-499.
19. Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab 2011; 14: 575-585.
20. Avramoglu RK, Basciano H, Adeli K. Lipid and lipoprotein dysregulation in insulin resistant states. Clin Chim Acta 2006; 368: 1-19.
21. Taghibiglou C, Carpentier A, Van Iderstine SC, Chen B, Rudy D, Aiton A et al. Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance. Evidence for enhanced lipoprotein assembly, reduced intracellular ApoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model. J Biol Chem 2000; 275: 8416-8425.
22. Toth PP. Insulin resistance, small LDL particles, and risk for atherosclerotic disease. Curr Vasc Pharmacol 2014; 12: 653-657.
23. Adeneye AA, Agbaje EO, Olagunju JA. Metformin: an effective attenuator of risperidone-induced insulin resistance hyperglycemia and dyslipidemia in rats. Indian J Exp Biol 2011; 49: 332-338.
24. Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS. The effects of met-formin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control. Diabetes Care 1998; 21: 701-705.
25. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. American Psychiatric Association: Washington, DC, USA, 1994.
26. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). American Psychiatric Press: Washington, DC, USA, 1996.
27. Ji LN, Pan CY, Lu JM, Li H, Li Q, Li QF et al. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin up-titration in Chinese patients with type 2 diabetes mellitus: study design and rationale of the vision study. Cardiovasc Diabetol 2013; 12: 118.
28. Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio Heart Study. Diabetes Care. 1997; 20: 1087-1092.
29. Andreasen NC. Scale for Assessment of Negative and Positive Symptoms. University of Iowa Press: Iowa City, USA, 1984.
30. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. US Dept of Health, Education, and Welfare: Rockville, MD, USA, 1976; 341-350.
31. Heide J, Zhang F, Bigos KL, Mann SA, Carr VJ, Shannon Weickert C et al. Differential response to risperidone in schizophrenia patients by KCNH2 genotype and drug metabolizer status. Am J Psychiatry 2016; 173: 53-59.
32. Apud JA, Zhang F, Decot H, Bigos KL, Weinberger DR. Genetic variation in KCNH2 associated with expression in the brain of a unique hERG isoform modulates treatment response in patients with schizophrenia. Am J Psychiatry 2012; 169: 725-734.
33. Mullugeta Y, Chawla R, Kebede T, Worku Y. Dyslipidemia associated with poor glycemic control in type 2 diabetes mellitus and the protective effect of met-formin supplementation. Indian J Clin Biochem 2012; 27: 363-369.
34. Carrizo E, Fernández V, Connell L, Sandia I, Prieto D, Mogollón J et al. Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study. Schizophr Res 2009; 113: 19-26.
35. Xu T, Brandmaier S, Messias AC, Herder C, Draisma HH, Demirkan A et al. Effects of metformin on metabolite profiles and LDL cholesterol in patients with type 2 diabetes. Diabetes Care 2015; 38: 1858-1867.
36. Baptista T, Rangel N, Fernández V, Carrizo E, El Fakih Y, Uzcátegui E et al. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophr Res 2007; 93: 99-108.
37. Hoenig MR, Sellke FW. Insulin resistance is associated with increased cholesterol synthesis, decreased cholesterol absorption and enhanced lipid response to statin therapy. Atherosclerosis 2010; 211: 260-265.
38. Pihlajamaki J, Gylling H, Miettinen TA, Laakso M. Insulin resistance is associated with increased cholesterol synthesis and decreased cholesterol absorption in normoglyc emic men. J Lipid Res 2004; 45: 507-512.
39. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000; 106: 453-458.
40. Ginsberg HN. Risk factors common to insulin resistance and atherosclerosis explain why diabetes is a cardiovascular disease. Am J Manag Care 2002; 3 Suppl: 5.
41. Rena G, Pearson ER, Sakamoto K. Molecular mechanism of action of metformin: old or new insights? Diabetologia 2013; 56: 1898-1906.
42. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007; 117: 1422-1431.
43. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223.
44. Henderson DC, Doraiswamy PM. Prolactin-related and metabolic adverse effects of atypical antipsychotic agents. J Clin Psychiatry 2008; 69: 32-44.
45. Bargiota SI, Bonotis KS, Messinis IE, Angelopoulos NV. The effects of antipsychotics on prolactin levels and women's menstruation. Schizophr Res Treatment 2013; 2013: 502697.